BACKGROUND: Microbial sensing by Toll-like receptors (TLR) and its negative regulation have an important role in the pathogenesis of inflammation-related cancer. In this study, we investigated the role of negative regulation of Toll-like receptors signaling and gut microbiota in the development of colitis-associated cancer in mouse model. METHODS: Colitis-associated cancer was induced by azoxymethane and dextran sodium sulfate in wild-type and in interleukin-1 receptor-associated kinase M (IRAK-M)-deficient mice with or without antibiotic (ATB) treatment. Local cytokine production was analyzed by multiplex cytokine assay or enzyme-linked immunosorbent assay, and regulatory T cells were analyzed by flow cytometry. Changes in microbiota composition during tumorigenesis were analyzed by pyrosequencing, and β-glucuronidase activity was measured in intestinal content by fluorescence assay. RESULTS: ATB treatment of wild-type mice reduced the incidence and severity of tumors. Compared with nontreated mice, ATB-treated mice had significantly lower numbers of regulatory T cells in colon, altered gut microbiota composition, and decreased β-glucuronidase activity. However, the β-glucuronidase activity was not as low as in germ-free mice. IRAK-M-deficient mice not only developed invasive tumors, but ATB-induced decrease in β-glucuronidase activity did not rescue them from severe carcinogenesis phenotype. Furthermore, IRAK-M-deficient mice had significantly increased levels of proinflammatory cytokines in the tumor tissue. CONCLUSIONS: We conclude that gut microbiota promotes tumorigenesis by increasing the exposure of gut epithelium to carcinogens and that IRAK-M-negative regulation is essential for colon cancer resistance even in conditions of altered microbiota. Therefore, gut microbiota and its metabolic activity could be potential targets for colitis-associated cancer therapy.

000      

00000naa a2200000 a 4500

001      

bmc14040828

003      

CZ-PrNML

005      

20170522122731.0

007      

ta

008      

140107s2013 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1097/MIB.0b013e318281330a $2 doi

035    __

$a (PubMed)23567778

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Klimesova, Klara

245    10

$a Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice / $c K. Klimesova, M. Kverka, Z. Zakostelska, T. Hudcovic, T. Hrncir, R. Stepankova, P. Rossmann, J. Ridl, M. Kostovcik, J. Mrazek, J. Kopecny, KS. Kobayashi, H. Tlaskalova-Hogenova,

520    9_

$a BACKGROUND: Microbial sensing by Toll-like receptors (TLR) and its negative regulation have an important role in the pathogenesis of inflammation-related cancer. In this study, we investigated the role of negative regulation of Toll-like receptors signaling and gut microbiota in the development of colitis-associated cancer in mouse model. METHODS: Colitis-associated cancer was induced by azoxymethane and dextran sodium sulfate in wild-type and in interleukin-1 receptor-associated kinase M (IRAK-M)-deficient mice with or without antibiotic (ATB) treatment. Local cytokine production was analyzed by multiplex cytokine assay or enzyme-linked immunosorbent assay, and regulatory T cells were analyzed by flow cytometry. Changes in microbiota composition during tumorigenesis were analyzed by pyrosequencing, and β-glucuronidase activity was measured in intestinal content by fluorescence assay. RESULTS: ATB treatment of wild-type mice reduced the incidence and severity of tumors. Compared with nontreated mice, ATB-treated mice had significantly lower numbers of regulatory T cells in colon, altered gut microbiota composition, and decreased β-glucuronidase activity. However, the β-glucuronidase activity was not as low as in germ-free mice. IRAK-M-deficient mice not only developed invasive tumors, but ATB-induced decrease in β-glucuronidase activity did not rescue them from severe carcinogenesis phenotype. Furthermore, IRAK-M-deficient mice had significantly increased levels of proinflammatory cytokines in the tumor tissue. CONCLUSIONS: We conclude that gut microbiota promotes tumorigenesis by increasing the exposure of gut epithelium to carcinogens and that IRAK-M-negative regulation is essential for colon cancer resistance even in conditions of altered microbiota. Therefore, gut microbiota and its metabolic activity could be potential targets for colitis-associated cancer therapy.

650    _2

$a zvířata $7 D000818

650    _2

$a azoxymethan $x toxicita $7 D001397

650    _2

$a western blotting $7 D015153

650    _2

$a karcinogeny $x toxicita $7 D002273

650    _2

$a kolitida $x chemicky indukované $x komplikace $7 D003092

650    _2

$a nádory tračníku $x etiologie $x metabolismus $x patologie $7 D003110

650    _2

$a cytokiny $x genetika $x metabolismus $7 D016207

650    _2

$a síran dextranu $x toxicita $7 D016264

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a průtoková cytometrie $7 D005434

650    _2

$a gastrointestinální trakt $x mikrobiologie $7 D041981

650    _2

$a kinázy asociované s receptory interleukinu-1 $x fyziologie $7 D053592

650    _2

$a mužské pohlaví $7 D008297

650    12

$a metagenom $7 D054892

650    _2

$a myši $7 D051379

650    _2

$a myši inbrední C57BL $7 D008810

650    _2

$a myši knockoutované $7 D018345

650    _2

$a messenger RNA $x genetika $7 D012333

650    _2

$a kvantitativní polymerázová řetězová reakce $7 D060888

650    _2

$a receptory interleukinu-1 $x metabolismus $7 D017472

650    _2

$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133

650    _2

$a signální transdukce $7 D015398

650    _2

$a regulační T-lymfocyty $x imunologie $x metabolismus $x patologie $7 D050378

650    _2

$a toll-like receptory $x genetika $x metabolismus $7 D051193

655    _2

$a časopisecké články $7 D016428

655    _2

$a Research Support, N.I.H., Extramural $7 D052061

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Kverka, Miloslav $u -

700    1_

$a Jirásková-Zákostelská, Zuzana $7 xx0117342

700    1_

$a Hudcovic, Tomas $u -

700    1_

$a Hrncir, Tomas $u -

700    1_

$a Stepankova, Renata $u -

700    1_

$a Rossmann, Pavel $u -

700    1_

$a Ridl, Jakub $u -

700    1_

$a Kostovcik, Martin $u -

700    1_

$a Mrazek, Jakub $u -

700    1_

$a Kopecny, Jan $u -

700    1_

$a Kobayashi, Koichi S $u -

700    1_

$a Tlaskalova-Hogenova, Helena $u -

773    0_

$w MED00002243 $t Inflammatory bowel diseases $x 1536-4844 $g Roč. 19, č. 6 (2013), s. 1266-77

856    41

$u https://pubmed.ncbi.nlm.nih.gov/23567778 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20140107 $b ABA008

991    __

$a 20170522123125 $b ABA008

999    __

$a ok $b bmc $g 1005224 $s 839340

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2013 $b 19 $c 6 $d 1266-77 $i 1536-4844 $m Inflammatory bowel diseases $n Inflamm Bowel Dis $x MED00002243

LZP    __

$a Pubmed-20140107